Objective To investigate the effect of Shenqi Maixintong(SQMXT)Capsules on in-stent restenosis(ISR)and inflammatory factors in patients after percutaneous coronary intervention(PCI).Methods A total of 60 patients with coronary heart disease after PCI in Guangzhou Hospital of Integrated Traditional and Western Medicine from December 2021 to Jan-uary 2023 were selected as the study objects and they were divided into control group and experimental group according to the random number table method,with 30 cases in each group.The control group was treated with the standard drug regimen recommended by the guidelines,and the experimental group was treated with SQMXT Capsules(4 capsules,tid)on the basis of the standard treatment for 24 weeks.After treatment,the traditional chinese medicine(TCM)syndrome efficacy was evalu-ated,the ISR and in-stent thrombosis were observed,and the serum levels of matrix metalloproteinase-9(MMP-9),inter-leukin-6(IL-6),interleukin-8(IL-8)and tumor necrosis factor(TNF-α)were measured.Results After treatment,the effi-cacy and score of TCM syndrome in the experimental group were higher than those in the control group,and the differences were statistically significant(P＜0.05).After treatment,the incidence of in-stent restenosis was lower than that of the control group,and the difference was statistically significant(P＜0.05).After treatment,there was no significant difference in stent thrombosis between the two groups(P＞0.05).After treatment,the serum levels of MMP,IL-6,IL-8,and TNF-α in the experimental group were lower than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion SQMXT Capsule can effectively inhibit the inflammatory response of endothelial cells,reduce the rate of ISR and improve the clinical symptoms by reducing the serum levels of MMP-9,IL-6,IL-8 and TNF-α.
维普
万方数据